Clinical trial

Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

NCT07152184

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE2

Study timeline

Study start (estimated)2026-10-01Date precision: day

Registry last updated2026-05-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Patient With Schizophrenia Spectrum Disorderunresolved

NLM Classification WM 203, Psychology:Schizophrenic Psychologyunresolved

Schizophrenia Spectrum and Other Psychotic Disordersunresolved

Interventions

Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - FlupDRUG

Sponsors & collaborators

University Hospital, Strasbourg, Francelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07152184 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.